Acute Myeloid Leukemia Refractory clinical trials

Explore recruiting acute myeloid leukemia refractory clinical trials.

Recruiting acute myeloid leukemia refractory studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Myeloid Leukemia Refractory trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE

France

Therapeutic exploratory (Phase II) EU CTIS Study details

First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

AML-NET : Acute Myeloid Leukemia treated with with NETrin Abs in combination with [AZACITIDINE + VENETOCLAX]

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)

Germany, Spain, Sweden, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Acute Myeloid Leukemia Refractory trials by city

Acute Myeloid Leukemia Refractory in Toronto Acute Myeloid Leukemia Refractory in Vancouver Acute Myeloid Leukemia Refractory in Montreal Acute Myeloid Leukemia Refractory in Calgary Acute Myeloid Leukemia Refractory in Edmonton Acute Myeloid Leukemia Refractory in Ottawa Acute Myeloid Leukemia Refractory in Winnipeg Acute Myeloid Leukemia Refractory in Quebec City Acute Myeloid Leukemia Refractory in Hamilton Acute Myeloid Leukemia Refractory in Kitchener Acute Myeloid Leukemia Refractory in London Acute Myeloid Leukemia Refractory in Halifax Acute Myeloid Leukemia Refractory in New York Acute Myeloid Leukemia Refractory in Los Angeles Acute Myeloid Leukemia Refractory in Chicago Acute Myeloid Leukemia Refractory in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease